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Abstract
Background:  CIWA-Ar  score  is  the  gold  standard  for  stratifying  severity  of  alcohol  withdrawal
syndrome  (AWS).
Aim:  To  identify  the  correlation  between  the  different  scales  used  in  patients  with  AWS,  and
with the  biochemical--haematological  proﬁle.
Material  and  methods: Prospective,  analytical  observational  study  in  49  patients  with  AWS  diag-
nosed between  February  2011  and  July  2012.  Maddrey,  Glasgow,  MELD,  CIWA-Ar  scores  and
laboratory  values  were  obtained  at  diagnosis.
Results:  There  was  no  correlation  between  CIWA-Ar  and  other  scales  (R2 =  0.001,  p  =  0.823,
95%CI);  however,  a  linear  relationship  (p  =  0.000,  95%CI)  was  found.  On  the  correlation  matrix,
CIWA-Ar was  not  associated  with  any  of  the  study  parameters.  There  were  no  signiﬁcant  differ-
ences in  length  of  stay  when  analyzed  by  type  of  treatment.
Conclusion:  CIWA-Ar  is  a  good  predictor  of  severity,  albeit  with  no  biochemical  or  hematic
correlation.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
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Análisis  factorial  y correlación  entre  el  protocolo  CIWA-Ar  con  el  perﬁl
bioquímico-hemático  en  pacientes  con  síndrome  de  supresión  etílica
Resumen
Antecedentes:  El  puntaje  CIWA-Ar  es  el  estándar  de  oro  para  estratiﬁcar  la  severidad  del
síndrome  de  supresión  etílica  (SSE).
Objetivo:  Identiﬁcar  la  correlación  entre  las  diferentes  escalas  utilizadas  en  pacientes  con  SSE,
así como  con  el  perﬁl  bioquímico-hemático.
Material  y  Métodos:  Estudio  prospectivo,  observacional-analítico,  incluyendo  49  pacientes  con
SSE atendidos  durante  febrero  2011  y  julio  2012.  Se  obtuvo  el  puntaje  Maddrey,  Glasglow,  MELD,
CIWA-Ar,  y  valores  de  laboratorios  al  momento  del  diagnóstico.
Resultados:  No  se  estableció  correlación  entre  CIWA-Ar  y  las  diversas  escalas  (R2=0.001,
p=0.823, 95%IC),  pero  si  entre  ellas  (p=0.000,  95%IC).  En  la  matriz  de  correlación,  CIWA-Ar
no se  asoció  a  ningún  parámetro.  No  existieron  diferencias  signiﬁcativas  del  tiempo  de  estancia
al analizar  por  tipo  de  tratamiento.
Conclusión:  CIWA-Ar  es  buen  predictor  de  severidad,  pero  sin  correlación  bioquímica  o
hemática.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
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requirements.  Levomepromazine  was  administered  intra-S.A. Todos  los  derechos  res
ackground
lcohol  withdrawal  syndrome  (AWS)  is  one  of  the  main
omplications  of  alcohol  abuse.  Approximately  8%  of  all  hos-
ital  admissions  are  due  to  manifestations  or  complications
ssociated  with  AWS,  and  between  20%  and  30%  of
atients  are  admitted  to  intensive  care  units.1 A  num-
er  of  mechanisms  are  involved  in  the  physiopathology  of
WS,  including  elevated  catecholamine  levels  secondary
o  inhibition  of  presynaptic    2  autoreceptor  activity,
omocysteine-mediated  NMDA  receptor  over-stimulation,
nd  diminished  GABA  receptor  afﬁnity.2 The  ﬁrst  clini-
al  manifestations  of  AWS,  usually  minor  symptoms,  such
s  tremor,  anxiety,  perspiration  and  palpitations,  appear
etween  6  and  24  h  following  the  last  intake  of  alco-
ol.  Following  this,  symptoms  increase  and  become  more
evere;  some  patients  present  delirium  tremens,  which
re  characterized  by  confusion,  hallucinations,  hyperten-
ion  and  fever.3 Most  patients  are  treated  in  accordance
ith  their  symptoms,  which  are  assessed  using  the  CIWA-
r  (Clinical  Institute  Withdrawal  Assessment  for  Alcohol,
evised)  protocol.4 The  CIWA-Ar  score  is  currently  the  gold
tandard  for  evaluating  the  manifestations  and  severity
f  AWS.5 Treatment  is  generally  based  on  anticonvulsant,
ympatholytic,  and  neuroleptic  agents.  Benzodiazepines,
hich  reduce  the  risk  of  seizures,  symptom  severity,
nd  the  risk  of  developing  delirium  tremens,  are  still
he  treatment  of  choice.6,7 Haloperidol  is  the  most  com-
only  used  neuroleptic,  particularly  in  the  presence  of
allucinations.8
Particular  care  should  be  taken  with  patients  presenting
ith  AWS  and  a  concomitant  disease,  such  as  pancreatitis,
hronic  obstructive  pulmonary  disease,  or  liver  failure  sec-
ndary  to  acute  alcoholic  hepatitis  or  cirrhosis,  as  any  of
hese  factors  can  increase  the  risk  for  complications  and
ortality.3,9 Patients  with  liver  failure  should  be  evaluated
sing  the  Glasgow  Alcoholic  Hepatitis  score,  and  the  MELD10
nd/or  Maddrey  score  (when  liver  failure  is  secondary  to
cute  alcoholic  hepatitis).11--14
m
a
dos.
Both  MELD  and  Maddrey  scores  use  biological  markers
ynthetized  in  the  liver  to  identify  patients  at  greater  risk
or  mortality.14,15 Zapata-Irissón  et  al.,  in  a  study  compar-
ng  both  scales  in  a Mexican  population,  conclude  that  both
re  equally  effective  for  determining  prognosis  in  clinical
ractice.15 As  the  CIWA-Ar  is  a  subjective,  clinical  score,  its
elationship  with  the  foregoing  scales  and  with  the  patient’s
iochemical  and  haematology  proﬁle  is  unclear.
The  aim  of  this  study  is  to  determine  the  correlation,
f  any,  between  the  CIWA-Ar  score  and  the  MELD,  Maddrey
nd  Glasgow  scores  used  to  assess  prognosis  in  patients  with
epatic  failure  and  AWS.  We  also  evaluated  the  correlation
etween  the  CIWA-Ar  score  and  blood  count  and  biochem-
stry  ﬁndings  at  the  time  of  admission.
atients, materials and methods
e  conducted  an  observational,  prospective,  descriptive
nd  analytical  study  in  a  population  of  patients  diagnosed
ith  alcohol  withdrawal  syndrome  admitted  to  the  Internal
edicine  Department  of  the  General  Hospital  of  Cuauti-
lán.  All  patients  were  initially  examined  in  the  emergency
oom.  Patients  requiring  ventilatory  support  were  excluded.
he  decision  to  start  antipsychotic  therapy  or  sedation  was
aken  by  the  attending  physician  in  each  case.  At  admission,
atients  were  assessed  using  the  study  scales  and  samples
ere  drawn  for  biochemistry  and  complete  blood  count.
ll  patients  gave  their  informed  consent  at  the  time  of
dmission.
reatment
atients  were  sedated  with  10  mg  intravenous  benzodi-
zepine  (diazepam)  every  4--8  h,  depending  on  individualuscularly  at  a  dose  of  25  mg  every  6--8  h.  Haloperidol  was
dministered  either  intravenously  or  intramuscularly  at  a
ose  of  5  mg  every  6  or  8  h  until  the  psychotic  episode  was
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Table  1  General  characteristics  of  patients  at  the  time  of
admission  to  the  accident  and  emergency  department.
Variable  Median  Range,
95%CI
Age  43  18--73
Gender  n  =  (%)
Men  47  (95.9)
Women  2  (4.1)
Seizures,  n  =  (%)
Present  26  (53.1)
Absent  23  (46.1)
Treatment,  n  =  (%)
Haloperi-
dol  +  levomepromazine
20  (40.8)
Diazepam
(alone)
04  (08.2)
Diazepam  +  haloperidol
11  (22.4)
Combination  or
3  or  more  drugs
14  (28.6)
Scales
CIWA-Ar  (at
diagnosis)
17  14--21
CIWA-Ar  (24  h)  19  13--20
Maddrey  14  15--26
MELD  score  14  05--29
Glasgow  score  06  05--15
Biochemical  proﬁle
Creatinine
(mg/dL)
01  0.5--9.9
Glucose  (mg/dL) 110  64--350
AST  (U/L) 174  48--1165
ALT (U/L)  089  38--479
Amylase
(mg/dL)
056  0--852
Lipase  (mg/dL)  223  0--1906
Bilirubin,  total
(mg/dL)
2.17  0.40--28.5
Bilirubin,  direct
(mg/dL)
0.91  0.0--21.70
Bilirubin,
indirect  (mg/dL)
1.20  0.0--6.80
Lactate
dehydrogenase
(UI/L)
284  0.0--1306
Uric  acid
(mg/dL)
4.30  0.0--17.50
Triglycerides
(mg/dL)
106  0.0--1098
Cholesterol
(mg/dL)
165  0.0--469
Albumin  (g/dL) 03.5 0.0--5.40
Sodium  (meq/L) 139  120--155
Potassium
(meq/L)
03.3  2.9--3.5
Chloride
(meq/L)
100  97.7--103
Table  1  (Continued)
Variable  Median  Range,
95%CI
Calcium
(mg/dL)
7.5  6.80--7.71
Phosphate
(meq/dl)
2.4  2.14--3.6
Magnesium
(mg/dL)
1.9  1.57--1.99
Complete  blood  count
Leukocytes
(×103/mcl)
8.26  7.97--10.62
Neutrophils
(×103/mcl)
6.55  6.33--8.84
Lymphocytes
(×103/mcl)
0.74  0.78--1.16
Monocytes
(×103/mcl)
0.51  0.45--0.69
Eosinophils
(×103/mcl)
0.08  0.24--0.86
Basophils
(×103/mcl)
0.34  0.32--0.61
Haemoglobin
(g/dL)
13.28  12.32--14.25
Haematocrit  (%) 42.1 37.3--43.07
Mean
corpuscular
volume
97.2 94.1--98.69
MCHC  33.2  32.80--33.46
Platelets
(×103/mcl)
116  108.67--160.13
Coagulation  time
Prothrombin
time
13  12.9--15.2
aPTT  27.5  27.3--32.5
INR  1.18  1.17--1.37
AST, aspartate aminotransferase; ALT, alanine-
aminotransferase; MCHC, mean corpuscular haemoglobin
concentration; aTTP, activated partial thromboplastin time;
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esolved.  Patients  presenting  with  seizures  were  treated
ith  benzodiazepines.  Steroids  were  only  used  in  patients
coring  higher  than  32  on  the  Maddrey  scale.
tatistical  analysis
ample  size  was  calculated  for  a  statistical  power  of  0.8
sing  Statistica  version  7  (StatSoft,  Inc., Tulsa,  Oklahoma).
he  resulting  size  was  49  patients  (95%CI,  2%  margin  of
rror).  Statistical  analysis  was  performed  using  IBM  SPSS
tatistics  for  Windows,  version  20  (Armonk,  New  York,  USA).
irst,  descriptive  statistical  methods  were  used  to  calcu-
ate  the  frequency  of  qualitative  variables  and  the  mean
alues  of  quantitative  variables.  A  correlation  analysis  was
erformed  to  compare  the  Maddrey,  MELD  and  Glasgow
cales  with  the  CIWA-Ar  assessment  protocol.  Following  this,
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inear  regression  was  used  to  analyze  correlated  variables.
e  also  performed  factor  analysis  on  the  29  blood  chemistry
nd  complete  blood  count  parameters  to  obtain  a  matrix
f  principal  components  using  a  Varimax  rotation.  Log10
ransformation  was  used  on  all  values  to  reduce  variance.
he  nonparametric  U-Mann  Whitney  test  was  used  to  deter-
ine  the  existence  of  a  signiﬁcant  difference  between  mean
IWA-Ar  scores  at  24  h  after  start  of  antipsychotic  therapy
nd  length  (days)  of  hospital  stay.  Signiﬁcance  was  set  at
 ≤  0.05  (95%CI).  Finally,  we  compared  mean  hospital  stay
days)  of  each  subgroup  with  their  Maddrey,  MELD  and  CIWA-
r  scores.
esults
 total  of  49  patients  were  included  between  February  2011
nd  July  2012;  most  were  men  (n  =  47,  95.9%).  Mean  time
rom  last  alcohol  intake  prior  to  hospitalization  was  3.4  days
range  1--15  days).  Approximately  46.9%  (n  =  23)  of  patients
resented  with  convulsions  at  the  time  of  admission.  Table  1
hows  the  general  characteristics  of  the  patients  and  the
reatment  given.
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Table  2  Components  matrix  of  biochemical  proﬁle  and  blood  cou
1  2  3  4
GlucLg  −0.083  −0.529  516  −
ASTLg 0.362  0.754  0.125  −
ALTLg −0.096  0.584  0.145  −
BilirubinLg 0.562  0.331  −0.286  −
LDHLg 0.358  0.534  0.385  
CholesterolLg  −0.699  0.074  0.488  −
TgLg 0.752  −0.089  0.472  −
AlbLg −0.589  0.169  0.671  −
SodiumLg −0.173  0.668  −0.374  
PotassiumLg  0.153  0.051  0.171  
ChlorideLg −0.123  0.686  −0.619  
CalciumLg −0.289  0.378  0.471  −
PhosphateLg  0.148  −0.640  0.471  
MgLg 0.378  −0.227  0.526  −
CBCLg 0.562  0.456  0.268  
NeutrophilsLg  0.522  0.490  0.259  
LymphocytesLg  0.139  −0.381  −0.039  −
MonocytesLg  0.541  0.452  0.426  
EosinophilsLg  −0.604  −0.219  −0.457  
BasophilsLg −0.875  0.052  −0.122  
HbLg −0.383  0.668  0.257  −
HCTLg −0.374  0.639  0.278  −
MCVLg −0.403  0.669  −0.074  −
MCHCLg −0.202  0.425  −0.096  
PlateletsLg −0.255  −0.328  0.017  
TPLg 0.931  −0.075  −0.237  −
INRLg 0.923  −0.078  −0.251  −
aTTPLg 0.740  0.241  −0.228  −
Alb, albumin; ALT, alanine aminotransferase; aPPTa, activated partial t
plete blood count; Gluc, glucose; Hb, haemoglobin; HTC, haematocrit; 
Lg, logarithm; Mg, magnesium; MCHC, mean corpuscular haemoglobin
time; Tg, triglycerides.L.  Carcan˜o-Calderón  et  al.
orrelation  and  regression  analysis  of  prognostic
cales and  CIWA-Ar  score
he  ﬁrst  step  consisted  in  establishing  whether  a  correlation
xisted  between  the  main  scales  used  in  patients  with  AWS
nd  liver  failure.  A  direct  correlation  was  found  between  the
addrey  scale  and  the  MELD  and  Glasgow  scales  (p  =  0.000,
5%CI).  There  was  no  correlation  between  severity  assessed
n  the  CIWA-Ar  scale  and  the  Maddrey,  MELD  and  Glasgow
cales  (Pearson  correlation  =  0.033,  −0.08,  0.029;  p  =  0.823,
.955,  0.842,  respectively).  Regression  analysis  showed  that
he  Maddrey  score  at  diagnosis  has  no  correlation  with  the
IWA-Ar  score  (R2 =  0.001,  p  =  0.823,  95%CI);  the  same  was
rue  of  the  Glasgow  score  (R2 =  0.001).
actor  analysis  of  the  biochemical  and
aematology  proﬁleactor  analysis  was  performed  using  biochemical  and
aematology  proﬁles  determined  at  the  time  of  diagno-
is.  The  result  of  the  components  is  shown  in  Table  2.
e  extracted  8  components,  the  principal  ones  being
nt  of  patients  with  alcohol  withdrawal  syndrome  at  diagnosis.
Component
 5  6  7  8
0.005  −0.410  −0.237  0.281  0.126
0.055  −0.042  −0.477  −0.046  0.107
0.099  −0.211  −0.616  0.156  0.335
0.436  −0.402  0.254  0.155  −0.014
0.277  0.206  −0.507  −0.044  −0.024
0.105  −0.026  −0.105  0.212  0.122
0.001  −0.081  0.029  −0.225  0.097
0.113  0.232  0.081  −0.051  −0.094
0.484  0.004  −0.080  −0.142  0.130
0.416  −0.081  0.489  −0.092  0.695
0.043  −0.048  0.158  −0.185  0.115
0.099  −0.313  0.056  −0.491  −0.152
0.001  0.392  0.074  0.081  0.297
0.051  −0.444  0.150  −0.235  0.071
0.595  0.110  0.093  0.043  −0.125
0.610  −0.027  0.126  0.037  −0.087
0.096  0.757  −0.184  0.034  0.150
0.015  0.114  0.137  0.117  −0.353
0.265  0.045  −0.144  −0.269  −0.021
0.162  −0.192  −0.019  −0.057  0.157
0.333  0.239  0.374  0.039  0.065
0.351  0.280  0.363  −0.040  0.073
0.103  0.213  −0.051  0.091  0.128
0.052  −0.296  0.190  0.709  −0.015
0.846  0.070  0.164  0.226  −0.110
0.137  −0.051  0.001  0.001  0.134
0.142  −0.055  −0.014  0.003  0.143
0.176  0.409  0.062  0.112  0.027
hromboplastin time; AST, aspartate aminotransferase; CBC, com-
INR, international normalized ratio; LDH, lactate dehydrogenase;
 concentration; MCV, mean corpuscular volume; PT, prothrombin
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Table  3  Differences  in  mean  CIWA-Ar  scores  at  diagnosis
and at  24  h  between  different  drug  therapies.
Comparison  of  therapeutic  strategies  p
Haloperidol  +  leV  vs.  diazepam  0.614
Haloperidol  +  leV  vs.  Haloperidol  +  diazepam  0.372
Haloperidol  +  leV  vs.  Haloperidol  +  leV  +  diazepam  0.726
Diazepam  vs.  haloperidol  +  leV  +  diazepam  0.873
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iDiazepam  vs.  haloperidol  +  diazepam  0.322
LeV, levomepromazine.
component  1  (glucose,  bilirubin,  cholesterol,  triglyceride,
albumin,  leucocyte  count,  neutrophil  count,  monocytes,
eosinophils,  prothrombin  time,  INR,  and  activated  partial
thromboplastin  time)  and  component  2  (AST,  ALT,  LDH,
sodium,  chloride,  phosphate,  haemoglobin,  haematocrit,
and  mean  corpuscular  volume).  The  remaining  components
only  include  a  few  isolated  variables  (magnesium,  platelet
count,  and  calcium).  When  the  CIWA-Ar  score  was  added
to  the  component  matrix,  it  was  placed  in  component  7,
together  with  mean  corpuscular  haemoglobin  concentration
(MCHC)  and  calcium.
Therapeutic  success
There  was  no  difference  between  mean  CIWA-Ar  score  at
admission  and  at  24  h  in  any  of  the  4  different  thera-
peutic  strategies  used  (Table  3).  Mean  length  of  stay  was
6  days  (6.1--8.7,  95%CI).  A  signiﬁcant  difference  in  this
parameter  was  only  found  between  patients  treated  with
haloperidol  +  levomepromazine  and  those  given  haloperi-
dol  +  diazepam  (p  =  0.009,  95%CI)  (Table  4).  There  was  no
difference  in  length  of  stay  between  patients  with  a  Mad-
drey  score  of  <  or  >  32  (p  =  0.665,  95%CI)  and  those  with  a
MELD  score  of  <  or  >  21  (p  =  0.807,  95%CI).  However,  differ-
ence  in  length  of  stay  between  patients  with  a  CIWA-Ar  score
of  <  8  and  >  20  (p  =  0.028)  was  signiﬁcant,  although  this  was
not  the  case  in  scores  between  9  and  20  points  (p  =  0.984).
Mortality  rate  during  follow-up  was  6.1%  (n  =  3).
Discussion
Correlation  between  scalesCorrelation  analysis  identiﬁed  a  positive  relationship
between  Maddrey,  MELD  and  Glasgow  scores.  This  is  simi-
lar  to  the  ﬁndings  of  Ali  et  al.  in  a  study  comparing  Maddrey,
Table  4  Difference  in  mean  hospital  stay  between  each
drug  therapy.
Comparison  of  therapeutic  strategies  p
Haloperidol  +  leV  vs.  diazepam  0.086
Haloperidol  +  leV  vs.  haloperidol  +  diazepam  0.009*
Haloperidol  +  leV  vs.  haloperidol  +  leV  +  diazepam  0.217
Diazepam  vs.  haloperidol  +  leV  +  diazepam  0.510
Diazepam  vs.  haloperidol  +  diazepam  0.122
LeV, levomepromazine.
* Statistically signiﬁcant.
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hild--Pugh  and  Glasgow  scores  in  respect  of  mortality  at  28
ays.16 Palaniyappan  found  similar  results  after  creating  a
OC  curve  at  30  and  90  days,  6  months,  and  1  year  to  eval-
ate  the  prognostic  utility  of  5  of  the  most  commonly  used
iver  failure  scales.  In  this  case,  the  only  exception  was  the
hild--Pugh  score,  which  failed  to  predict  mainly  short-term
ortality.17 Adding  CIWA-Ar  score  to  the  model  showed  no
orrelation  with  any  of  the  study  scales.  This  could  be  due
o  the  fact  that  the  CIWA-Ar  scale  mainly  evaluates  clinical
anifestations,  not  biochemical  parameters.
actor  analysis
actor  analysis  also  failed  to  determine  correlation  between
cores  and  biochemical  parameters  or  blood  count  in  the
omponent  matrix.  As  in  the  foregoing  case,  we  believe
hat  the  absence  of  correlation  is  due  to  lack  of  relation-
hip  between  AWS  severity,  mainly  in  early  events,  and
xisting  liver  failure,  which  affects  liver  synthesis  tests.
orrelation  was  only  established  between  CIWA-Ar  score
nd  various  polymorphisms,  mainly  oxidative  stress  markers
uch  as  malondialdehyde  (MDA)  and  superoxide  dismutase
SOD).18
ifferences  between  therapeutic  strategies
o  difference  was  found  between  the  4  therapies  used  in
erms  of  mean  hospital  stay.  Considering  that  3  of  the  treat-
ents  administered  included  benzodiazepines,  we  found  no
vidence  that  length  of  stay  was  shortened  when  other  ther-
peutic  strategies  were  combined  with  these  drugs.  This  is
onsistent  with  the  evidence  in  the  literature,  where  both
ymptom-triggered  and  ﬁxed-dose  benzodiazepines  (mainly
iazepam)  are  the  treatment  of  choice.19,20 According  to
 Cochrane  review  of  64  studies  (4309  patients),  benzo-
iazepines  protected  against  speciﬁc  AWS  manifestations,
articularly  seizures,  when  compared  with  placebo  and
ven  with  other  sedatives.  This  is  why  they  continue  to
e  the  ﬁrst  line  therapy  in  these  patients.21,22 We  also
ompared  drug  groups  in  terms  of  length  of  hospital  stay.
n  this  regard,  we  found  no  differences  between  benzodi-
zepines  alone  or  in  combination  with  one  or  more  sedative
r  neuroleptic  agents.  Jaeger  et  al.  reported  similar  ﬁnd-
ngs  with  symptom-triggered  benzodiazepines.  They  found
o  difference  between  the  on-demand  and  ﬁxed-dose  group
n  terms  of  length  of  stay  (days),  seizures  or  delirium
remens).23 Haloperidol  was  only  used  in  patients  presenting
ith  delirium  tremens.  Several  studies  have  reported  the
eneﬁt  of  this  drug  in  controlling  hallucinations,  mainly
hen  administered  on  the  basis  of  symptom-orientated  dose
djustment.24--27 Administration  of  benzodiazepines  in  com-
ination  with  other  drugs  is  not  a  novel  approach  in  AWS,28
articularly  diazepam  +  halopediol;25 however,  this  combi-
ation  has  not  been  shown  to  be  superior  to  benzodiazepines
lone.29 Levomepromazine  is  usually  reserved  for  patients
resenting  with  a  schizophrenic  break.30,31 Its  usefulness
n  AWS  therapy  is  based  mainly  on  anecdotal  ﬁndings.  In
ur  experience,  combination  therapy  with  haloperidol  or
iazepam  gave  similar  results,  both  in  terms  of  CIWA-Ar
core  at  24  h  and  length  of  hospital  stay,  with  no  signiﬁcant
dverse  events.
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260  
ortality
he  mortality  rate  was  6.1%  overall,  with  no  difference  in
he  number  of  deaths  in  respect  of  severity  on  the  CiWA-
r  (Log  Rank  [Mantel--Cox],  0.52),  MELD  score  (Log  Rank
Mantel--Cox],  0.973)  and  Maddrey  (Log  Rank  [Mantel--Cox],
.978)  scores.  Mortality  was  low  in  our  cohort,  a  ﬁnding  con-
istent  with  other  similar  series.  Nevertheless,  mortality  was
igher  in  patients  requiring  admission  to  intensive  care  units
1--60%  of  admissions  to  intensive  care  units).32
The  results  presented  and  discussed  here  were  obtained
rom  a  series  of  patients  admitted  to  the  Hospital  General
n  Cuautitlán,  a  referral  hospital  for  Mexico  State  treat-
ng  patients  not  eligible  for  national  health  insurance.  The
ocial  and  demographic  characteristics  of  this  population
o  not  necessarily  reﬂect  those  of  the  Mexican  population
s  a  whole,  and  our  results  could  be  biased  by  variables
eyond  our  control  and  inherent  to  the  type  of  population
reated.  These  variables  include  age  (mainly  young  adults),
ow  socioeconomic  level  (which  could  be  a  risk  factor  for
reater  metabolic  susceptibility  due  to  malnutrition),33,34
o  name  just  a  few.  As  this  study  was  not  designed  as  a
ontrolled  clinical  trial,  we  were  unable  to  apply  better
election  criteria  to  study  subjects.  An  interesting  aspect  to
xplore  in  future  studies  on  this  topic  would  be  the  possible
orrelation  between  length  of  alcohol  addiction  or  number
f  prior  AWS  episodes  and  treatment  outcomes.
In  conclusion,  alcohol  withdrawal  syndrome  is  one  of  the
rincipal  diseases  associated  with  alcohol  abuse.  Clinical
cales  such  as  CIWA-Ar  are  useful  for  determining  the  appro-
riate  sedation  protocol,  but  show  no  correlation  with  other
ssessment  scales  or  with  the  patient’s  biochemical  proﬁle
r  blood  count.  We  believe  that  benzodiazepines  should  con-
inue  to  be  the  treatment  of  choice.  The  addition  of  other
euroleptic  drugs  had  no  effect  on  the  length  of  hospital
tay  or  the  degree  of  agitation.  Researchers  should  continue
o  search  for  new  strategies  or  explore  the  use  of  new  drugs,
uch  as  5-HT  receptors  blockers.
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